Bank of New York Mellon Corp Acquires 87,089 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Bank of New York Mellon Corp boosted its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 48.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 265,514 shares of the biopharmaceutical company's stock after acquiring an additional 87,089 shares during the period. Bank of New York Mellon Corp owned about 0.47% of Agios Pharmaceuticals worth $8,725,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Erste Asset Management GmbH acquired a new stake in shares of Agios Pharmaceuticals in the third quarter valued at approximately $97,199,000. Vestal Point Capital LP acquired a new position in shares of Agios Pharmaceuticals during the third quarter valued at approximately $33,767,000. State Street Corp increased its stake in shares of Agios Pharmaceuticals by 10.2% during the third quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company's stock valued at $103,586,000 after acquiring an additional 216,484 shares during the period. Frazier Life Sciences Management L.P. increased its stake in shares of Agios Pharmaceuticals by 19.7% during the third quarter. Frazier Life Sciences Management L.P. now owns 1,044,154 shares of the biopharmaceutical company's stock valued at $46,392,000 after acquiring an additional 172,180 shares during the period. Finally, Loomis Sayles & Co. L P increased its stake in shares of Agios Pharmaceuticals by 36.4% during the third quarter. Loomis Sayles & Co. L P now owns 612,366 shares of the biopharmaceutical company's stock valued at $27,208,000 after acquiring an additional 163,503 shares during the period.

Remove Ads

Analyst Upgrades and Downgrades

A number of research analysts recently commented on AGIO shares. StockNews.com lowered shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Friday, February 14th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. HC Wainwright started coverage on shares of Agios Pharmaceuticals in a research note on Monday, February 24th. They set a "buy" rating and a $58.00 price objective on the stock. Scotiabank raised their price objective on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a "sector outperform" rating in a research note on Monday, December 9th. Finally, Royal Bank of Canada raised their price objective on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an "outperform" rating in a research note on Tuesday, December 10th. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $56.57.

Insider Buying and Selling at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction on Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the sale, the insider now owns 18,906 shares of the company's stock, valued at $608,395.08. This trade represents a 12.92 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 4.93% of the company's stock.

Agios Pharmaceuticals Price Performance

Agios Pharmaceuticals stock traded down $0.79 during midday trading on Tuesday, reaching $31.20. The stock had a trading volume of 640,179 shares, compared to its average volume of 739,145. The firm's fifty day simple moving average is $33.67 and its two-hundred day simple moving average is $41.67. Agios Pharmaceuticals, Inc. has a twelve month low of $27.14 and a twelve month high of $62.58. The firm has a market cap of $1.79 billion, a price-to-earnings ratio of 2.75 and a beta of 0.90.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. As a group, sell-side analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.